Furthermore, we examined cellular sensitivity in these cells to determine whether DLBCL cell lines have differential sensitivity to doxorubicin, a significant component of R-CHOP therapy that is known to induce DSBs (52,53). This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.